Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6/9/25 19:13 | 6/9/25 | TVGN | Health | BioPrd | Biological Products, (No Diag | Saadi Ryan H. | NJ | DOT | CEO | S | -1,769 | 1.23 | 0 | -1,438 | -1 | 117,008 | D | ||||||||||||||
3/14/25 21:02 | 3/12/25 | TVGN | Health | BioPrd | Biological Products, (No Diag | Flomenberg Neal | NJ | O | See Rema | S | -254 | 1.09 | 0 | -233 | -6 | 3,596 | D | ||||||||||||||
3/11/25 20:52 | 3/7/25 | TVGN | Health | BioPrd | Biological Products, (No Diag | Flomenberg Neal | NJ | O | See Rema | S.m | -232 | 1.09 | 0 | -212 | -5 | 3,829 | D | ||||||||||||||
3/6/25 21:41 | 3/4/25 | TVGN | Health | BioPrd | Biological Products, (No Diag | Flomenberg Neal | NJ | O | See Rema | S.m | -250 | 1.17 | 0 | -214 | -5 | 4,040 | D | ||||||||||||||
10/18/24 21:57 | 10/17/24 | TVGN | Health | BioPrd | Biological Products, (No Diag | Flomenberg Neal | NJ | O | See Rema | S | -1,747 | 1.62 | 0 | -1,079 | -20 | 4,254 | D | ||||||||||||||
7/18/23 17:36 | 7/17/23 | LGST | Financ | AcqCo | Blank Checks | Corbin Capital Partners, L.P. | NY | T | S | -24,778 | 10.68 | 0 | -2,320 | -100 | 0 | I | |||||||||||||||
6/8/23 06:05 | 6/7/23 | LGSTU | Financ | AcqCo | Blank Checks | Semper Paratus Sponsor LLC | NY | T | S | -8,989 | 1.00 | 0 | -8,989 | -68 | 4,294 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |